BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 35701522)

  • 1. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
    Lauer EM; Mutter J; Scherer F
    Leukemia; 2022 Sep; 36(9):2151-2164. PubMed ID: 35701522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of circulating tumor DNA in central nervous system lymphoma.
    Foerster AK; Lauer EM; Scherer F
    Semin Hematol; 2023 Jul; 60(3):150-156. PubMed ID: 37442670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
    Cirillo M; Craig AFM; Borchmann S; Kurtz DM
    Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: current challenges for clinical utility.
    Dang DK; Park BH
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
    Lakhotia R; Roschewski M
    Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of circulating tumor DNA in indolent B-cell lymphomas.
    Lakhotia R; Roschewski M
    Semin Hematol; 2023 Jul; 60(3):164-172. PubMed ID: 37419716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA in Lymphoma.
    Kambhampati S; Zain J
    Curr Hematol Malig Rep; 2022 Dec; 17(6):298-305. PubMed ID: 36214943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
    Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
    Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-free DNA in large B-cell lymphoma: MRD and beyond.
    Sworder BJ; Kurtz DM
    Semin Hematol; 2023 Jul; 60(3):142-149. PubMed ID: 37474409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
    Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
    Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas.
    Meriranta L; Pitkänen E; Leppä S
    Semin Hematol; 2023 Jul; 60(3):132-141. PubMed ID: 37455222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
    Malla M; Loree JM; Kasi PM; Parikh AR
    J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma.
    Meriranta L; Alkodsi A; Pasanen A; Lepistö M; Mapar P; Blaker YN; Jørgensen J; Karjalainen-Lindsberg ML; Fiskvik I; Mikalsen LTG; Autio M; Björkholm M; Jerkeman M; Fluge Ø; Brown P; Jyrkkiö S; Holte H; Pitkänen E; Ellonen P; Leppä S
    Blood; 2022 Mar; 139(12):1863-1877. PubMed ID: 34932792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA in Lymphoma: Principles and Future Directions.
    Roschewski M; Rossi D; Kurtz DM; Alizadeh AA; Wilson WH
    Blood Cancer Discov; 2022 Jan; 3(1):5-15. PubMed ID: 35015693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.